for Pain Management
Pain is transmitted to the brain as an electrical stimulus from the peripheral nerves where it is perceived as pain. It is known that sodium entering nerve cells is needed for the transmission of electrical stimuli and therefore transmitting pain signals. Halneuron and its active ingredient, Tetrodotoxin, blocks the sodium entry which diminishes the conduction of nerve impulses along nerve fibres, and as a consequence, relieves pain.
1. Chemotherapy-Induced Neuropathic Pain (CINP)
Chemotherapy Induced Neuropathic Pain (CINP) patient population in the US, 5 major European markets and Japan was estimated to be ~2 million cases in 2018 and is projected to grow at a cumulative annual growth rate of 1.1% (Data Monitor March 2018).
CINP is an area of unmet medical need for patients treated with some of the most common cancers. CINP is caused by oral or intravenous chemotherapy given to treat the primary tumour or metastases. Common chemotherapy agents that cause peripheral neuropathy include taxanes (paclitaxel and docetaxel), platinum-based drugs (cisplatin and oxaliplatin), vinca alkaloids (vincristine), thalidomide, and proteasome inhibitors (bortezomib). CINP can begin after the first dose of chemotherapy and is often related to cumulative dose. CINP manifests in hands, feet, and sometimes face and can extend in a glove and stocking distribution to affect lower arms and lower legs. The pain is typically a pricking or burning feeling and may be described as an “electric sensation”.
CINP is a major limitation on the amount of chemotherapy that can be administered to treat cancer and can seriously impact day-to-day function often progressing to a painful disabling condition, causing significant loss of function and quality of life.
There are currently no approved pain therapies for CINP.